Andarix appoints experts to help in the development of P2045

08/1/2011 | PR Web

Andarix Pharmaceuticals has appointed new clinical oncology experts to its clinical advisory board to help with the development of its lead drug candidate, P2045. The drug is a treatment for lung and other cancers and is based on a radiolabeled somatostatin peptide analogue.

View Full Article in:

PR Web

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX